The Director General of the World Health Organization is Dr. Tedros Adhanom Ghebreyesus.

The Director General of the World Health Organization is Dr. Tedros Adhanom Ghebreyesus.

The Director General of the World Health Organization is Dr. Tedros Adhanom Ghebreyesus.

The Director General of the World Health Organization is Tedros Adhanom Ghebreyesus.

The Director General of the World Health Organization is Dr. Tedros Adhanom Ghebreyesus.

Taiwan faced significant medication shortages following an epidemic, with efforts by local companies like Singhui to fill the gaps in drug supply.

The US experienced medication shortages, specifically of chemotherapy drugs like carboplatin and cisplatin, according to a survey of cancer centers.

The US experienced medication shortages, affecting the treatment of patients, including those with Hodgkin's lymphoma.

The United States experienced medication shortages, specifically a lack of amoxicillin.

Taiwan has been experiencing medication shortages, with over 100 kinds of commonly used drugs being out of stock, affecting the country's health insurance system and patients' access to necessary medicines.

"Authorities propose addressing medication shortages by enhancing supply chain transparency and investment, making swift decisions, and investing in healthcare, which includes diversifying manufacturing locations and improving inventory management."

"Authorities propose increasing investment in supply chains and healthcare to address medication shortages, emphasizing the need for substantial funding and international cooperation."

Authorities suggest addressing medication shortages by increasing investment in supply chains and healthcare, making swift and bold decisions, and providing support measures such as financial subsidies and priority review and approval.

The healthcare worker shortage is predicted to occur by 2030, according to the World Health Organization.

The healthcare worker shortage is predicted to occur by 2035, with an estimated shortfall of 18 million workers.

The healthcare worker shortage is predicted to reach 18 million by 2035, according to the WHO.

China's national medical insurance directory includes 58 kinds of rare disease medications, covering about 67% of listed rare disease drugs, to make these medications more affordable for patients.

China's national medical insurance directory includes 45 rare disease medications, covering 26 rare diseases, as of 2022.

To combat corruption in healthcare, strict punitive measures and independent anti-corruption bodies are needed to prevent and prosecute corrupt practices.

"Independent anti-corruption bodies and strict punitive measures are crucial in combating corruption in healthcare, promoting transparency and accountability in health policies and services."

The main cause of medication shortages is the pursuit of short-term profits by pharmaceutical companies, leading to a lack of production and prioritizing profits over human health.

Medication shortages are primarily caused by the lack of production due to low profits, resulting from government price reductions for health insurance drugs.

Medication shortages are caused by low production and pursuit of short-term profits, resulting from extremely low prices negotiated by Group Purchasing Organizations (GPOs) with wholesalers.

Medication shortages are caused by lack of production and pursuit of short-term profits, with some manufacturers suspending production due to events like the Chinese New Year, and authorities responding by asking manufacturers to speed up production.

The main cause of medication shortages is attributed to pharmaceutical companies' focus on short-term profits, resulting in a disparity between drug production and demand.

A medication shortage occurred due to insufficient supply from manufacturers or distributors, leading to an increase in demand for certain drugs and a spillover effect on other medications.

The medication shortage is caused by insufficient supply from manufacturers or distributors due to supply chain disruptions.

A global shortage of antibiotics has been reported, with 28 out of 35 countries experiencing a deficiency in penicillin-type drugs, due to insufficient supply from manufacturers or distributors caused by a combination of factors including manufacturing difficulties, high energy prices, and unexpected demand spikes.

The medication shortage is likely due to a combination of factors, including insufficient supply from manufacturers or distributors and misconceptions about generic drugs, which can be addressed through government investment in public education.

A medication shortage of paracetamol in Ireland was caused by insufficient supply from manufacturers or distributors, with some suppliers expecting resupply in January 2023, while others still had stock available.

Medication shortages in Taiwan affected over 100 types of commonly used drugs, including antibiotics and pain killers.

Medication shortages in Taiwan affected a range of products, including many medications such as pain drugs and oral paste drugs, with some special instructions still lacking despite efforts to fill the gap.

Medication shortages, including anti-cancer drugs like carboplatin and cisplatin, have been reported, with a significant percentage of centers experiencing shortages.

Medication shortages in Taiwan affected various types of drugs, including antibiotics, fever, and diarrhea medications, as announced by the Ministry of Health and Welfare.

Medication shortages occurred in Taiwan, affecting the supply of prescription drugs in hospitals and clinics.

The American Pharmacists Association reported a record shortage of all types of drugs in the U.S., with particular concern over the lack of sterile injectable drugs, including chemotherapy and emergency medicines.

Sterile injectable drugs, including cancer chemotherapy and emergency drugs, are in short supply.

A medication shortage was reported, with the Ministry of Health and Welfare announcing the 15 most scarce drugs, including antibiotics, antipyretics, and anti-diarrheals.

The medication shortages in the U.S. include cancer chemotherapy drugs and emergency medicines, which are sterile injectable drugs, prompting concern from the American Pharmacists Association.

Medication shortages affect cancer chemotherapy drugs, with a significant percentage of cancer centers reporting shortages of specific drugs like carboplatin and cisplatin.

Medication shortages affect various types of drugs, including cancer chemotherapy medications such as methotrexate, 5-fluorouracil, fludarabine, and hydrocortisone.

Medication shortages, including cancer chemotherapy drugs and potentially emergency medicines, are a significant concern globally, with the cancer drug shortage being an ongoing issue.

The medication shortages affect cancer chemotherapy drugs, including those used to treat Hodgkin's lymphoma.

The medication shortage persists due to low prices negotiated with drugmakers, which has led importers to refrain from delivering medicines to pharmacies, ultimately depriving patients of necessary medication.

Low prices negotiated with drugmakers are suspected to be a contributing factor to the medication shortage, as they result in meager profits for manufacturers, leading to reduced production of certain drugs.

The suspected contributing factor to the medication shortage is the low prices negotiated with drugmakers, which may lead to reduced production or discontinuation of certain drugs.

Low prices negotiated with drugmakers are suspected to be a contributing factor to the medication shortage.

Low prices negotiated with drugmakers are suspected to contribute to medication shortages due to limited returns on investment in new drugs and restrictions on generic drug supply.

Medication shortages are caused by manufacturing problems and quality issues, largely due to government price reductions leading to low profits for manufacturers and compromised drug quality.

Medication shortages are caused by manufacturing problems and quality issues, affecting various drug classes, including sterile injectable generic drugs and cancer chemotherapy drugs.

The root causes of medication shortages are primarily due to manufacturing problems and quality issues, including supply chain gaps and downtime.

Medication shortages are caused by manufacturing problems and quality issues, contributing to a growing global concern.

Medication shortages are caused by manufacturing problems and quality issues, as seen in the case of a factory in India being closed due to quality issues, leading to a shortage of a generic chemical drug.

There is a shortage of paracetamol in Ireland due to increased cases of Covid-19 and the winter flu.

Medication shortages occurred due to importers being unsatisfied with the dollar exchange rate used for pricing, leading to a refusal to deliver medicines to pharmacies.

Medications such as methotrexate, 5-fluorouracil, fludarabine, and hydrocortisone were found to be in short supply, in addition to carboplatin and cisplatin.

Carboplatin and cisplatin were the chemotherapy medications in short supply in US cancer centers, with 93% and 70% of treatment centers reporting shortages, respectively.

"US cancer centers experienced shortages of chemotherapy medications, including carboplatin and cisplatin, according to a survey by the National Comprehensive Cancer Network."

Medications in short supply, apart from antibiotics, include pain relievers, tuberculosis medications, and skin infection treatments.

Medication shortages are a growing concern globally, with various types of medications being affected, including pain relievers, tuberculosis medications, and skin infection treatments, in addition to antibiotics.

The NCCN is concerned about systemic challenges contributing to cancer medication shortages, which have a widespread impact despite efforts to address the issue.

The NCCN attributes cancer medication shortages to systemic challenges that have been ongoing for decades.

The Director General of the World Health Organization is Dr. Tedros Adhanom Ghebreyesus.

Title:

Content: World Health Organization releases list of essential medicines for multiple sclerosis, cancer and heart
Sunday ، 30 July 2023 02: 00 PM
Director General of Global Health
I wrote Hope Allam.
Leave a comment and read the comments of the readers.
The World Health Organization (WHO) recently published updated new versions of its Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLc), which include important new medicines for the treatment of multiple sclerosis, cancer, infectious diseases and cardiovascular diseases.
These treatments can have a very significant impact on global public health without jeopardizing the health budgets of low- and middle-income countries.
Dr Tedros Adhanom Ghebreyesus, Director-General of WHO, said: “For more than 40 years, countries around the world have relied on the WHO List of Essential Medicines as the ultimate evidence-based evidence as the most important medicines to achieve the greatest impact on health, rising prices and supply chain disruptions mean that all countries now face increasing problems in ensuring consistent and equitable access to many quality assured essential medicines. Faithful.
For the 2023 update, 85 applications, including more than 100 medicines and formulations, were considered by the WHO Expert Committee on the Selection and Use of Essential Medicines. The recommended changes bring the total number of essential medicines and essential medicines for children to 502 and 361 respectively.
Multiple sclerosis drugs "MS"
Multiple sclerosis is a chronic disease that weakens the nervous system and affects nearly 2.8 million people worldwide, so far, no drugs to treat it have been included in essential drugs, in 2023, 3 drugs that can delay or slow its progression - cladribine and glatiramer acetateo rituximab - were added to essential drugs to fill an important gap due to the large global burden of MS The inclusion of these drugs as treatment options for MS with different management methods, different prices (with availability of generic drugs and bioavailable alternatives) and various recommended uses, aims to facilitate improved access to treatment for people living with MS worldwide, the decision to support the use of off-label rituximab is supported by strong evidence of its efficacy and safety for this indicator.
The list is an important tool for achieving universal health coverage, providing guidance to governments, health facilities and those purchasing medicines that are of the best value in terms of benefits to individuals and communities.
“Due to the evidence and increased affordability of rituximab, including the availability of pre-qualified biostimulants, it has been prioritized over the alternatives on the label as an essential drug for the treatment of recurrent multiple sclerosis and progressive relapse. ”
Cardiovascular Drugs
Fixed dose combinations of multiple drugs (commonly called "multipill") for the prevention of cardiovascular disease, particularly cholesterol-lowering agents with one or more blood pressure lowering agents with and without acetylsalicylic acid (aspirin) to essential drugs for the first time.
Infectious diseases.
New medicines listed for infectious diseases include:
Ceftuluzan + tazobactam, a group of "back up" antibiotics effective against multi-drug resistant bacteria, including hard-to-treat infections caused by carbapenem resistant Pseudomonas aeruginosa, priumanide for the treatment of multi-drug resistant tuberculosis or rifampicin-resistant tuberculosis, Ravidasvir (used with sofosbuvir) for the treatment of hepatitis virus infection Chronic epidemiological in adults, monoclonal antibodies to Ebola virus disease.
Cancer Drugs
Two new cancer treatments have been added: doxorubicin linked to Kaposi ’ s sarcoma and pegfilgrastim to stimulate white blood cell production and reduce the toxic effect of certain cancer drugs on bone marrow, the indications for many pediatric cancer drugs already included in pediatric essential drugs have been extended to include new types of pediatric cancers (macrolymphoma, Langerhans cells, lymphoma In addition, those not recommended for inclusion include several patented, high-priced cancer drugs due to concerns about affordability and feasibility in low-resource settings, some of which were evaluated and rejected during previous committee meetings.
Leave a comment and read the comments of the readers.
No comments on the news.
Leave a comment
Your comment will appear after the review.

The Director General of the World Health Organization is Dr. Tedros Adhanom Ghebreyesus.

Title:

Content: This came in a panel discussion held during the Forum – which was broadcast on its official website a little while ago – and highlighted that the global pandemic preparedness system needs sustained political will and investments to ensure that the global healthcare supply chain responds effectively to any crisis.
If we don ’ t take pandemic preparedness seriously now, the lives of millions more will be at stake.
The SARS, Ebola and COVID-19 crises have tested the world ’ s ability to deal with outbreaks of epidemics and infectious diseases, and the global pandemic preparedness system needs sustained political will and investments to ensure that the global healthcare supply chain responds effectively to the crisis.
“Eight years ago, when the Ebola outbreak proved that the world was no better prepared for outbreaks, there was more talk and some action, ” participants said.
This included the establishment of the Epidemiological Supply Chain Network (PSCN), by the World Health Organization, the World Economic Forum, the World Bank, the World Food Programme, the US Centers for Disease Control and Prevention and more than 60 companies.
However, nearly three years after the COVID-19 pandemic – the worst global health crisis in a century – many of the same supply chain vulnerabilities remain, and although partnerships, such as PSCN and national efforts have somewhat reduced the severity of supply chain disruptions during the epidemic, efforts to develop a global pandemic preparedness system have not yet mobilized the will. “The sustainable policy and investment needed to ensure that global health care is delivered in a way that can respond effectively to any crisis. ”
The Forum recommended seven key actions to address this issue:
- Providing political will and sustainable financing.
Although crises often lead to an influx of short-term spending, money quickly dries up as memories fade and priorities change.
Genuine global health security requires global financing mechanisms that enable sustainable investment and ultimately break panic and fear.
- Geographical diversification in manufacturing; achieving greater geographical diversity requires more than just investing in new factories.
Long-term contracts and financial guarantees are needed to maintain the manufacturing of important health-care materials in diverse locations.
- Improved inventory management.
In addition to strengthening stocks of personal protective equipment (PPE) at local, regional and national levels, we must manage medical stocks more intelligently.
- Establish platforms for data exchange and enhanced transparency.
Through globally focused PSCN and various national efforts, while progress has been made, encouraging responsible information sharing between public and private partners requires substantial additional funding.
Promote the free flow of goods.
Over the past three years, government restrictions on exports have played an important role in exacerbating the lack of product distribution.
While governments ’ desire to protect their people in times of crisis is understandable, international cooperation to allow the free flow of key products reduces the risk of viral spread.
- Strengthen coordinated early warning systems for epidemics.
Strengthening health systems and improving primary care.
Dr Tedros Adhanom Ghebreyesus, Director-General of WHO, said: “Universal health coverage and health emergencies are cousins – two sides of the same coin.
Significant and sustained investments are needed if we are to reap the benefits of expanded access to care. ”

The Director General of the World Health Organization is Dr. Tedros Adhanom Ghebreyesus.

Title:

Content: OPEN APP
Home >News >World >WHO adds new drugs to its essential medicines’ list
Listen to this article

Prices of cancer, diabetes, antimicrobials, antifungal drugs and tobacco cessation medicines may decline in India with the World Health Organization (WHO) including these drugs in the new edition of its Model Lists of Essential Medicines and Essential Medicines for Children published on Friday.

Antimicrobial drugs and those for fungal diseases such as mucormycosis surged during the pandemic, especially in the second wave. WHO’s updated essential medicines’ list includes 20 new medicines for adults and 17 for children and specifies new uses for 28 already-listed medicines.

WHO said high prices for both new, patented medicines and older medicines such as insulin continue to keep some essential medicines out of reach for many patients.

WHO’s model lists of essential medicines refer to those medicines that satisfy the priority healthcare needs of most of the population.

WHO noted that diabetes is spreading faster in low- and middle-income countries.

“Too many people who need insulin encounter financial hardship in accessing it or go without it and lose their lives. Including insulin analogues (an altered form of insulin) in the essential medicines’ list, coupled with efforts to ensure affordable access to all insulin products and expand use of biosimilars, is a vital step towards ensuring everyone who needs this life-saving product can access it," said Dr Tedros Adhanom Ghebreyesus, director-general, WHO.

As per International Diabetes Federation, 463 million people have diabetes globally with 88 million people in South-east Asia. Of this, 77 million are in India with 8.9% prevalence of diabetes in the population.

WHO noted that insulin production is concentrated in a small number of manufacturing facilities, and three firms control most of the global market. The lack of competition has led to high drug prices that are prohibitive for many people and health systems, it said.

“Inclusion in the list means that biosimilar insulin analogues can be eligible for WHO’s prequalification programme; WHO prequalification can result in more quality-assured biosimilars entering the international market, creating competition to bring prices down and giving countries a greater choice of products," said WHO.

Public health experts in India appreciated the move.

“Overall, this step of the WHO is welcome, specifically in relation to availability of life and heart saving SGLT2 inhibitor drugs at primary level. However, decision of provision of insulin analogues at primary levels is intriguing because these cost 2-5 times more than regular insulin and add nothing to efficacy in lowering blood sugar, apart from lower tendency to cause hypoglycemia. At primary level (and at all levels), low-cost regular insulins work as effectively as any highly publicized expensive insulins," said Dr Anoop Misra, chairman at Fortis-C-DOC and president of Diabetes Foundation (India).

In the case of cancer treatment, four new drugs were added to the model lists—Enzalutamide as an alternative to abiraterone for prostate cancer; Everolimus for subependymal giant cell astrocytoma (SEGA), a type of brain tumour in children; Ibrutinib, a targeted medicine for chronic lymphocytic leukaemia; and Rasburicase for tumour lysis syndrome, a serious complication of some cancer treatments.

Subscribe to Mint Newsletters
* Enter a valid email
* Thank you for subscribing to our newsletter.

Never miss a story! Stay connected and informed with Mint. Download our App Now!!

Close
×
Edit Profile
My ReadsRedeem a Gift CardLogout

The Director General of the World Health Organization is Tedros Adhanom Ghebreyesus.

Title:

Content: Global Mental Health Issues Saw Sharp Rise During Pandemic: WHO

Nearly one billion people worldwide suffer from some form of mental disorder, according to latest UN data a worrying figure as it includes around one in seven teenagers

UNITED NATIONS, (APP - UrduPoint / Pakistan Point News - 18th Jun, 2022 ) :Nearly one billion people worldwide suffer from some form of mental disorder, according to latest UN data a worrying figure as it includes around one in seven teenagers.

To make matters worse, in the first year of the coronavirus pandemic, rates of common conditions such as depression and anxiety, went up by more than 25 per cent, the UN health agency (WHO) said on Friday.

In its largest review of mental health since the turn of the century, the World Health Organization has urged more countries to get to grips with worsening conditions.

"Everyone's life touches someone with a mental health condition," WHO Director-General, Tedros Adhanom Ghebreyesus said in a statement. "Good mental health translates to good physical health and this new report makes a compelling case for change.

"The inextricable links between mental health and public health, human rights and socioeconomic development mean that transforming policy and practice in mental health can deliver real, substantive benefits for individuals, communities and countries everywhere. Investment into mental health is an investment into a better life and future for all." Even before COVID-19 hit, only a small fraction of people in need of help had access to effective, affordable and quality mental health treatment, WHO said, citing latest available global data from 2019.

For example, more than 70 per cent of those suffering from psychosis worldwide, do not get the help they need, the UN agency said.

The gap between rich and poor nations highlights unequal access to healthcare, as seven in 10 people with psychosis receive treatment in high-income countries, compared to only 12 per cent in low-income countries.

The situation is more dramatic for cases of depression, WHO said, pointing to gaps in assistance across all countries including high-income ones - where only one third of people who suffer from depression receive formal mental health care.

And although high-income countries offer "minimally-adequate" treatment for depression in 23 per cent of cases, this drops to just three per cent in low and lower middle-income countries.

"We need to transform our attitudes, actions and approaches to promote and protect mental health, and to provide and care for those in need," WHO's Tedros said. "We can and should do this by transforming the environments that influence our mental health and by developing community-based mental health services capable of achieving universal health coverage for mental health.

The Director General of the World Health Organization is Dr. Tedros Adhanom Ghebreyesus.

Title:

Content: Friday 23 Dhu al-Hijjah 1443 AH - 22 July 2022 |
Programs
Watch our latest episodes online
Good news for cancer and diabetes patients
Cancer and diabetes are among the most common diseases in the world, affecting millions of people.
The World Health Organization (WHO) on Friday published the new version of its model lists of essential and pediatric medicines, which include new treatments for various cancers, insulin analogues and new oral medicines for diabetics and antibacterial and antifungal agents.
The lists aim to address global health priorities and identify the drugs that provide the greatest benefits, which should be available and affordable to all, yet the high prices of both new patented medicines and older medicines, such as insulin, continue to keep some essential medicines out of the reach of many patients.
Dr Tedros Ghebreyesus, Director-General of the World Health Organization (WHO), said: “Diabetes is on the rise globally and rising faster in low- and middle-income countries, and many people who need insulin face financial difficulties getting it or going without it and lose their lives.
Cancer, on the other hand, is the leading cause of death worldwide, causing nearly 10 million deaths in 2020, and seven in ten cases occur in low- and middle-income countries.
New breakthroughs in cancer treatment have been made in recent years, such as drugs targeting tumor-forming molecular properties, some of which offer much better results than “traditional ” chemotherapy for many cancers.
Four new cancer drugs have been added to the model lists: Epiraterone has been replaced by anzalotamide for prostate cancer, Iverolimus has been added to treat Sega tumor that spreads in children, Iproteinib for chronic lymphocytic leukemia, and Razboricis for tumor lysis syndrome, which is a serious complication associated with cancer treatment.

Taiwan faced significant medication shortages following an epidemic, with efforts by local companies like Singhui to fill the gaps in drug supply.

Title:

Content: The spillover effect of drug shortage shows that Singhui indicates an increase in demand for drugs
The problem of lack of drugs continues to burn, local pharmaceutical company Singhui (1734-TW) said that at present, most of the indicated drugs are in short supply, but during the lack of drugs feel the spillover effect, including pain drugs, oral paste drugs, etc., the demand has increased significantly.
After the epidemic, Taiwan faced the biggest shortage of drugs, and Singhui pointed out that with the establishment of a drug supply platform by the Ministry of Health and Welfare, there is no shortage of many generic drugs, but some special instructions are still lacking, and Singhui is filling the gap.
Heng Hui further said that due to the shortage of special instructions, clinics and pharmacists will provide Heng Fai's medicines instead.
In addition to the increase in demand for pharmaceutical products, Sinphar ’ s health products performance has grown synchronously this year, and with the increase in visibility of star products, it will drive the performance in the second half of the year.
The company estimates that this year's full-year revenue is expected to exceed 3 billion yuan for the first time in history.
In addition, the subsidiary Xingguo (4192-TW) will start to adjust the operating structure, initially planning to agent anti-tumor drugs, has been locked in some drugs, expect to start to contribute to revenue this year.
Extended reading
Related Posts

The US experienced medication shortages, specifically of chemotherapy drugs like carboplatin and cisplatin, according to a survey of cancer centers.

Title:

Content: Advertisement

U.S. cancer centers report ongoing shortage of chemotherapy drugs

By Cara Murez, HealthDay News
In all, 72% of cancer centers surveyed reported a continued shortage of carboplatin. And 59% were still seeing a shortage of cisplatin. Photo by klbz/Pixabay

U.S. cancer centers continue to have shortages of commonly used chemotherapy drugs, a new survey shows, though the medications are not as scarce as they were last June.

The National Comprehensive Cancer Network (NCCN), a nonprofit alliance of leading cancer centers, surveyed its network in September.

In all, 72% of cancer centers surveyed reported a continued shortage of carboplatin. And 59% were still seeing a shortage of cisplatin.

Advertisement

These two platinum-based generic chemotherapy medications are recommended for treating many different cancers. Overall, 86% of centers surveyed said they were short on at least one type of anti-cancer drug. A survey in June showed that 93% of cancer centers had a shortage of carboplatin, and 70% of cisplatin.

"Everyone with cancer should have access to the best possible treatment according to the latest evidence and expert consensus guidelines," said Dr. Robert Carlson, chief executive officer for NCCN.

Advertisement

"Drug shortages aren't new, but the widespread impact makes this one particularly alarming. It is extremely concerning that this situation continues despite significant attention and effort over the past few months. We need enduring solutions in order to safeguard people with cancer and address any disparities in care," Carlson said in a NCCN news release. Twenty-nine of the NCCN's member institutions responded to the September survey. They include leading academic centers across the United States. The findings may not reflect additional challenges that smaller community practices serving rural and marginalized patients are experiencing. The centers surveyed were using strict waste management strategies, so nearly all were still able to provide the medications to all patients who needed them. Other medications in short supply included methotrexate, with 66% of centers reporting a shortage; 5-fluorouracil, with 55% falling short; fludarabine at 45%; and hydrocortisone at 41%.

"These drug shortages are the result of decades of systemic challenges," said Alyssa Schatz, NCCN's senior director of policy and advocacy. "We recognize that comprehensive solutions take time."

Schatz said the network appreciates those who have put forth proposals to improve investment in generics.

"At the same time, we have to acknowledge that the cancer drug shortage has been ongoing for months, which is unacceptable for anyone impacted by cancer today," Schatz said. "These new survey results remind us that we are still in an ongoing crisis and must respond with appropriate urgency."

Advertisement

The organization is continuing to advocate for more supplies.

CNN recently reported that two other drugs used for cancer, vinblastine and dacarbazine, went into shortage in September.

"These drugs are particularly used to treat patients with Hodgkin's lymphoma. Hodgkin's lymphoma is probably one of the most curable types of cancers out there," Dr. Doug Hawkins of the Children's Oncology Group, a research organization, told CNN.

"The problem is never-ending. It is horrible," he added. "I mean, to say to a patient, 'we know how to treat your child, but we can't get the drugs,' and this is America, and it's 2023 -- it's crazy."

More information

The White House has more on strengthening the supply chain for cancer drugs.

Copyright © 2023 HealthDay. All rights reserved.

Latest Headlines

The US experienced medication shortages, affecting the treatment of patients, including those with Hodgkin's lymphoma.

The United States experienced medication shortages, specifically a lack of amoxicillin.

Title:

Content: Experts have recorded a shortage of antibiotics in the world due to the increase in the number of infectious diseases.
On December 21, writes the Financial Times with reference to the head of the group of the World Health Organization (WHO) for the supply of medicines and ensuring access to them Lisa Hedman, reports Day.Az.
Twenty-eight of the 35 countries for which WHO collects data are deficient in penicillin-type drugs.
In the United States and Canada complained about the lack of amoxicillin.
Less is known about the situation in poor or small countries, according to Hedman.
It is noted that in addition to the difficulties experienced by pharmaceutical manufacturers in the pandemic, the current situation is complicated by high energy prices, and this leads to a decrease in profits of companies.
In addition, countries, according to Hedman, did not expect that in the first year without masks, respiratory infections would hit the population so hard.
In addition to antibiotics, pharmacists also complain about the lack of painkillers, drugs for tuberculosis and drugs for skin infections.

Taiwan has been experiencing medication shortages, with over 100 kinds of commonly used drugs being out of stock, affecting the country's health insurance system and patients' access to necessary medicines.

Title:

Content: My channel
* Drag categories can be customized sorting
Recover Default OK
Setup
Alert
The owner of a Chinese restaurant in LA was shocked and resigned after receiving 13,000 gas bills.
One Killed, One Injured in Sunset District Explosion in Jinshan, Originally a Family Drug "Workshop"
News Review / Drugs and Eggs Out of Stock Government Incompetent and Interventionist
In economics, the “invisible hand ” refers to the fact that under the full operation of the price mechanism, the supply and demand of the market will reach the most appropriate balance, as if there are invisible hands guiding the general.
However, what people have seen in Taiwan in recent years is that the government's dirty hands frequently and aggressively manipulate prices, affecting supply and demand, and the market not only loses the freedom to operate, but also affects the supply, demand and quality of many goods.
Recently, the domestic egg price has risen and the supply has not continued, and many daily drugs have broken out of stock, and grass-roots pharmacies even have to "change drugs" to save themselves; the culprit is the government officials who are incompetent and love to intervene.
The egg shortage in Taiwan has lasted for more than a year.
The main reason is that the Council of Agriculture uses various methods to intervene in egg prices and wants to keep prices down, resulting in a lack of willingness to produce eggs and a reluctance to increase the amount of chicken raised.
Under such rigid market conditions, the supply of eggs is always insufficient, and the pressure of rising egg prices can not be alleviated, and the egg shortage problem of course continues to exist.
Chen Jizhong, chairman of the Council of Agriculture, said that he only promised to solve the "egg shortage" and did not say to solve the "egg price"; no one believes this statement, the facts prove that he has neither solved the egg shortage nor solved the egg price, and the egg market is still a lump of paste.
Eggs are ordinary people's daily food, whether the supply is insufficient or the price rises, will affect the people's sense of stability.
The formation of eggs from the shell to the laying of eggs, about 18 weeks.
Taiwan ’ s egg shortage, however, has lasted for 60 weeks, showing that excessive government intervention has caused egg farmers to lose their willingness to increase production, which has paralyzed market supply.
So far last year, the Russian-Ukrainian war has caused global grain prices to soar and feed prices to rise; the government does not let egg farmers reflect the cost, no matter how unreasonable repression.
Looking at it again, many commonly used Chinese and Western medicines have been out of stock recently, which is also related to government policy intervention; but compared to the egg shortage, the situation is more complicated and more worrying.
These drugs, from antibiotics, pain killers, fever reduction drugs, gastrointestinal drugs, soft stool, etc., a total of more than 100 kinds of drugs are commonly used in people's lives.
In the past six months, the situation has occurred that community pharmacies have repeatedly failed to call drugs, and many pharmacies can only respond with other pharmacies to meet the needs of patients.
Taiwan ’ s health insurance is known for its convenience and low price, but now there is a scene of “no medicine to buy ”. Who is violating the people ’ s right to health?
The Food and Drug Administration ’ s explanation for this “drug shortage ” is that many pharmaceutical companies have recently switched to production of Covid-19 related drugs, thus crowding out other drugs.
In fact, the global epidemic has come to an end, and this statement is outdated. The medical community believes that the more critical factor is that the government continues to reduce the price of health insurance drugs, and the proportion of drug costs in medical expenses should not be too high.
As a result of long-term repression, many drugs or pharmaceutical products are not produced by manufacturers because of their meager profits.
Worse, in addition to the lack of drugs, the quality of the drugs is constantly discounted, thus undermining the efficacy of the drugs.
After three years of fighting the epidemic, people have seen the Ministry of Health and Welfare fervently control the brand and quantity of vaccines, drugs, and reagents.
Of course, the free market is not a panacea for economic development. The government does not leave everything to the market to follow the flow, that is, to enjoy the benefits of the country and the people.
But on the other hand, such as the Tsai government's enthusiasm for regulation, intervention and subsidies, completely ignore the complex and interlaced factors in the market mechanism, and finally let the people suffer from price increases and shortage of goods, which is also an inevitable result.
Egg and medicine are just two recent examples. When it comes to oil and electricity, it is even more difficult to solve.
The Tsai government played a "visible hand", but the lack of goods and quality fell, but the people suffered. (Excerpt from the United Daily News editorial)
Pharmacy Epidemic Health Insurance
The last one.
Chen Yingjie instigated the elder sister to falsify the promissory note and was sentenced in February of 3 years.
The next one.
Tainan male followed female netizens home to molest mother and daughter social worker home visit a shocking scene
Extended reading
Super-popular
More >

"Authorities propose addressing medication shortages by enhancing supply chain transparency and investment, making swift decisions, and investing in healthcare, which includes diversifying manufacturing locations and improving inventory management."

"Authorities propose increasing investment in supply chains and healthcare to address medication shortages, emphasizing the need for substantial funding and international cooperation."

Authorities suggest addressing medication shortages by increasing investment in supply chains and healthcare, making swift and bold decisions, and providing support measures such as financial subsidies and priority review and approval.

Title:

Content: Health · Life
Continue to do a good job in the prevention and control of rare diseases (people's opinion)
Shin Shaotetsu
December 05, 2022 07: 47 Source: People 's Daily - People' s Daily
Continue to strengthen research on rare diseases and ensure drug use, and further strengthen capacity building for the prevention and treatment of rare diseases
In 2022, the national medical insurance drug catalog will be adjusted, and a separate reporting channel will be opened for rare disease drugs, and rare disease drugs will be given priority in the medical insurance drug catalog.
So far, 45 drugs for rare diseases have been included in the national medical insurance drug catalog, covering 26 rare diseases.
The good news announced at the 2022 China Rare Disease Conference held recently has made many rare disease patients very happy.
General Secretary Xi Jinping pointed out in the report of the 20th National Party Congress: "To ensure the health of the people in the strategic position of giving priority to development."
Raising the level of treatment for rare diseases is related to the happiness of thousands of families.
Since the 18th National Congress of the Communist Party of China (CPC), the Party Central Committee and the State Council have attached great importance to the prevention and control of rare diseases, guiding relevant departments and parties to strengthen the supply of rare diseases research, diagnosis and treatment and drug research and development, and improving the medical security system for rare diseases.
The establishment of a rare disease catalogue, the establishment of a national network for rare disease diagnosis and treatment, and the establishment of the China rare disease alliance... a series of powerful measures have promoted the development of rare disease prevention and treatment, and brought hope to more patients.
Rare diseases are a challenging disease field and a major public health problem.
At present, there are more than 7,000 known rare diseases in the world, such as Gosher's disease, asymptotic freeze and albinism.
Because of the low incidence, variety, complex pathology, the difficulty of diagnosis and treatment of rare diseases, most of the diseases do not have effective treatment drugs.
Because of the high cost of research and development, some rare disease treatment drugs are expensive.
To solve the difficult problem of “difficult to diagnose, difficult to treat and expensive to treat ” rare diseases, the whole society needs to form a joint force to further improve the medical security system for rare diseases.
To prevent and control rare diseases, we must first grasp the prevention and control at the source, pay attention to prevention and early detection.
Of the known rare diseases, about 80% are inherited diseases caused by genetic mutations, and about half of them develop in childhood.
Strengthening prenatal screening and newborn genetic disease screening can achieve eugenics and early detection and early treatment of rare diseases, and reduce the long-term impact of rare diseases on patients and families.
In recent years, China has continuously increased medical and health investment and improved the birth defect prevention and treatment system.
There are more than 4,000 premarital health care institutions and 498 prenatal diagnostic institutions nationwide, providing a strong guarantee for the prevention and treatment of rare diseases.
There are few cases of rare diseases, involving blood, orthopedics, nerves, kidneys, respiratory, skin and severe diseases, and it is difficult to diagnose and treat, which is easy to cause misdiagnosis and missed diagnosis.
In 2019, the National Health and Health Commission selected 324 hospitals to set up a national rare disease diagnosis and treatment cooperation network, and established a two-way referral and remote consultation mechanism.
As the leading hospital, Beijing Union Hospital has established a national multi-disciplinary diagnosis and treatment platform for rare diseases, and the "one-stop treatment plan" has shortened the average diagnosis time of patients from the previous four years to less than four weeks, effectively improving the diagnosis and treatment efficiency.
With the continuous response of medical institutions at all levels, more high-level experts will join the diagnosis and treatment platform in the future, and the conditions for diagnosis and treatment of rare diseases will be further improved.
The problem of lack of medication for rare diseases has always been highlighted.
It is necessary to strengthen the guarantee of drug use for patients, increase the research and development of rare diseases drugs, and encourage universities, scientific research institutes, hospitals and pharmaceutical enterprises to participate in the research and development of rare diseases drugs through the establishment of rare diseases drug research and development funds, financial subsidies, tax incentives, priority review and approval, and other support measures.
A life-saving medicine has been produced, and patients have to be able to use it.
On the one hand, under the premise of ensuring the normal operation of the medical insurance fund, we will explore the inclusion of more rare diseases drugs in the medical insurance catalogue; on the other hand, for rare diseases drugs with large amounts, we can effectively reduce the price of drugs through drug negotiations.
At present, China has approved more than 60 rare disease drugs on the market, the national organization of rare disease drug negotiations average price reduction of more than 50%, rare disease patients access to medication is constantly improving.
On the road of building a healthy China, we must care for every group in difficulty and must not give up.
With the continuous advancement of China's rare disease medical security system, the right to life and health of rare disease patients will be better guaranteed.
Continue to strengthen the research and drug use of rare diseases, and further strengthen the capacity of rare diseases prevention and treatment, we will be able to better protect the health of the people and improve the health and well-being of the people.
People 's Daily (05 / 12 / 2022)
(Editor: Sun Hongli, Yang Di)
Related News

The healthcare worker shortage is predicted to occur by 2030, according to the World Health Organization.

Title:

Content: How natural language processing can help relieve the healthcare worker shortage

This article is brought to you thanks to the collaboration of The European Sting with the World Economic Forum.

Author: Tashfeen Suleman, CEO, CloudMedx

  • The WHO predicts a shortage of 18 million health workers by 2030.
  • A new survey shows the “biggest pain points” affecting these workers: increasing use of tech can add even more layers of documentation.
  • Healthcare workers want to spend more time caring directly for patients, and less on paperwork. Natural language processing (NLP) is a game changer. It can take over a lot of this work, freeing healthcare personnel to spend more time on direct care.

Across the world, fears are rising about a lack of nurses, doctors, and healthcare technicians in the coming years. The World Health Organization predicts a shortage of 18 million health workers by 2030.

There was already a shortage before the COVID-19 pandemic, but the last few years have exacerbated the problem. Experiencing burnout, exhaustion and mistreatment, many in the sector, especially nurses, have quit their jobs. But there are also other reasons for the shortage as well. For example, in the United States, many doctors are reaching retirement age just as the population of elderly people is expanding – meaning more people will need healthcare from fewer providers.

In addition to attracting young people to careers in medicine, other solutions are needed. One of these is to put new, emerging technologies to good use. But this is a very difficult challenge in healthcare. Unfortunately, the sector has a history of bringing in technologies that are meant to help but end up making things more complicated.

Tech as relief and burden

A new global survey of healthcare workers shows how concerned they are about this. A large majority (70%) say they believe digital health technology will enable positive transformation. But virtually the same number (69%) say these technologies will present a “challenging burden.”

I’ve seen this problem in action for years. The most prominent example involves electronic health records (EHRs). These were meant to improve care and make things much more efficient. And while they have brought benefits, they have also increased the amount of time healthcare staff have to spend dealing with documentation.

One study found that time spent on direct patient care dropped by more than 8 percent at one center. Another found that nurses perceive a high workload due to all the documentation. In a survey published in March, U.S. physicians were polled about the “documentation burden” presented by EHRs. Majorities said they’re spending too much time on documentation, and that it’s reducing the time they have for patient care. And one-third said they’re spending two hours or more completing documentation outside of work hours each day.

It shouldn’t be this way. Technologies can be designed to handle more administrative tasks so that healthcare workers spend more time in direct patient care. The more we relieve the documentation burden, the more patients can get the attention they need.

The potential of NLP

Natural language processing is a technology focused on helping machines process information as humans do. Several companies have been working to apply this to the world of medicine.

When doctors and nurses need relevant information from a patient’s healthcare records, they should not have to go digging through long lists of information collected over the years. Instead, technology should be able to read through all the text and automatically pull up relevant information for a patient’s treatment. One study published in 2020 found that specifically designed algorithms could do so with 96% accuracy.

Similarly, healthcare providers should be able to speak into their phones or other devices and have the information they provide automatically entered into healthcare records through NLP. When a patient comes into an emergency department complaining of certain symptoms, NLP can help pull up relevant information from the patient’s records – for example, a family history that could show the patient has an elevated risk for a heart attack. So doctors and nurses would see that information automatically pop up when they open the patient’s file.

Of course, there is always a possibility of machine errors, just as there are possibilities of human errors. It’s important to have healthcare personnel look at the information and doublecheck it. But there’s no need for them to spend extra time finding the information in the first place – just as they should not have to scroll through long forms with lots of text fields in order to input information. Technology should do all that for them.

There are also other ways to use NLP. For example, this technology has been built into AskSophie, a tool in which people can describe symptoms they’re having in order to learn about patients with similar ailments and what’s causing them.

Serving the needs of healthcare workers through technology

NLP is just one tool that can help relieve burdens on doctors and nurses and strengthen global healthcare for the future. Artificial intelligence can help deliver a more holistic approach to health by showing government and healthcare leaders the social determinants of health that must be addressed in different areas. Algorithms can help predict patient flow so hospitals have a better sense of how much staff they’ll need at any moment. And companies are developing new ways to monitor patients in need from afar. The possibilities are endless.

The key is to incorporate the needs of healthcare workers in the development of new technologies. The more people are freed to spend time caring for patients and avoiding burdens of documentation, the more people will join and stay in the healthcare field. This will make the global health outlook only stronger.

%d bloggers like this:

The healthcare worker shortage is predicted to occur by 2035, with an estimated shortfall of 18 million workers.

Title:

Content: Global Healthcare Facing Severe Workforce Shortage by 2035

TL;DR Breakdown

  • Global healthcare is in a crisis, with a projected shortage of 18 million workers by 2035.
  • Digital health integration and AI are vital solutions to enhance patient care and address biases.
  • Connectivity and shared learning are key to bridging healthcare gaps and improving the system.

Healthcare systems worldwide face complex challenges, including an aging population, disparities in healthcare access, and a scarcity of healthcare professionals. Alarming projections from the World Health Organization (WHO) estimate a severe shortfall of 18 million healthcare workers by 2035, further exacerbated by the recent pandemic.

During a recent keynote session titled “Health that Connect, Tech that Cares,” Hal Wolf, HIMSS President and CEO, advocated for a proactive approach. He suggested that integrating digital health seamlessly into healthcare facilities is a promising solution. This involves deploying advanced technologies and providing comprehensive training to the workforce.

The crucial role of AI in personalized care

Central to this strategy is the adoption of artificial intelligence (AI) to deliver personalized care more efficiently. Hospitals have now harnessed predictive modeling capabilities, enabling care teams to prioritize cases and redirect time from manual patient testing to direct patient care. Wolf emphasizes recognizing AI as a valuable tool in the healthcare toolkit.

Wolf further emphasizes that a clear vision must guide any development of AI applications. It is crucial to identify and rectify biases that might inadvertently affect AI applications. Additionally, the accuracy and integrity of healthcare data, particularly in electronic medical records (EMRs) and data structures, are paramount for informed decision-making.

Robust connectivity is another critical factor to consider. This entails ensuring that care teams can access essential tools and applications anywhere. Notably, initiatives like Indonesia’s plan to introduce satellite connectivity for rural community health centers are helping bridge healthcare disparities in underserved communities.

Hal Wolf concludes by urging participants to openly share their experiences and insights gained during their digital transformation journeys. This collaborative approach, encompassing successes and challenges, is essential for continuously improving healthcare systems.

An impending global healthcare crisis

The global healthcare sector is on the brink of a severe crisis. Challenges, including a rapidly aging population, persistent healthcare disparities, and a widening workforce gap, have created a daunting scenario. The WHO’s prediction of an 18 million health worker shortage by 2035 is a stark warning for all stakeholders.

Digital health integration

To mitigate this impending crisis, experts recommend a multifaceted approach. At the forefront is the seamless integration of digital health into healthcare facilities. This transformation involves incorporating technology as an integral part of healthcare infrastructure and investing in workforce training to harness its full potential.

The role of artificial intelligence (AI) in healthcare is paramount. With predictive modeling capabilities, hospitals can streamline patient care by prioritizing cases efficiently. However, it is essential to view AI as a valuable tool with limitations, as Hal Wolf emphasized.

Developing AI applications requires a clear vision and a commitment to addressing biases that may inadvertently affect algorithms. Furthermore, maintaining and improving the integrity of electronic medical records (EMRs) and data structures is crucial to ensure reliable decision-making.

Efforts to bridge healthcare gaps extend to ensuring robust connectivity. Initiatives like Indonesia’s plan to introduce satellite connectivity for rural community health centers exemplify the commitment to ensuring healthcare resources are accessible, even in underserved areas.

Learning from experience

Sharing lessons learned becomes paramount as healthcare organizations embark on digital transformation journeys. Hal Wolf’s call to openly discuss both successes and challenges fosters an environment of collective growth.

The global healthcare sector faces an imminent workforce crisis that necessitates immediate action. The integration of digital health, AI-driven personalized care, bias mitigation, data integrity assurance, and robust connectivity are crucial steps to address these challenges. Collaboration, open dialogue, and shared experiences will be pivotal as healthcare systems prepare for the impending workforce shortfall worldwide.

Disclaimer. The information provided is not trading advice. Cryptopolitan.com holds no liability for any investments made based on the information provided on this page. We strongly recommend independent research and/or consultation with a qualified professional before making any investment decisions.

The healthcare worker shortage is predicted to reach 18 million by 2035, according to the WHO.

China's national medical insurance directory includes 58 kinds of rare disease medications, covering about 67% of listed rare disease drugs, to make these medications more affordable for patients.

Title:

Content: Health · Life
Let rare disease patients have a doctor, medicine, and protection
Li He
January 11, 2023 07: 51 Source: Science and Technology Daily
53%
In recent years, relevant departments have strongly supported the prevention and protection of rare diseases, and strengthened the supply of rare diseases research, diagnosis and treatment and drug research and development.
According to statistics, as of the end of November 2022, 89 drugs for the treatment of 45 rare diseases have been approved in China, and the number of rare diseases that can be treated in China accounts for 53% of the number of rare diseases that can be treated in the world.
On January 8 this year, the on-site negotiations on the national medical insurance drug catalog in 2022 were officially concluded.
Among them, 19 drugs for rare diseases, including Fabric's disease, Pompeii's disease, Gosher's disease, pulmonary hypertension and spinal muscular atrophy, set a new record.
Rare diseases are also called "orphan diseases".
According to the definition given in the "China Rare Disease Definition Research Report 2021", diseases with a neonatal incidence of less than one in 10,000, a prevalence of less than one in 10,000, and a number of diseases with a disease of less than 140,000, can be rare diseases.
Although the incidence of rare diseases is extremely low, but there are many kinds of diseases, the total number of patients is not a lot.
As of February 2022, there are more than 20 million rare disease patients in China, and more than 200,000 new patients are added every year.
Qiao Jie, an academician of the Chinese Academy of Engineering and executive vice president of Peking University, said that more than 7,000 rare diseases have been found in the world, about 80 percent of which are hereditary diseases and about 50 percent of which occur in childhood.
"Disease without medicine", "medicine without medicine" and "medicine without insurance" are common "crux" faced by patients with rare diseases.
Build a network of diagnosis and treatment, solve the problem of "no medical care"
Because rare diseases are rare and the number of patients with a single disease is very small, doctors, especially grass-roots hospitals, have insufficient ability to recognize and diagnose rare diseases, which restricts the improvement of rare diseases diagnosis and treatment ability.
The first step in the treatment of diseases is correct diagnosis, and difficult to diagnose is the first difficulty encountered by rare disease patients. In September 2021, a rare disease patient weighing only 18 kg was admitted to Beijing University of Aeronautics and Astronautics.
A Beijing doctor who happened to return to his hometown to visit his family suggested that he go to Peking University First Hospital for detailed investigation, so that sail, who is suffering from congenital muscular dystrophy, has an opportunity for early treatment.
According to the "2020 China Rare Disease Comprehensive Social Survey" released by the China Rare Disease Alliance, 15.5% of the more than 20,000 patients participating in the survey need to experience 1-4 years of diagnosis, and 5% of patients need to experience 5-20 years of diagnosis, with an average diagnosis time of 4.26 years.
Of these, 42% also experienced a misdiagnosis.
In order to improve the diagnosis and treatment of rare diseases, in 2018, the five departments of the National Health and Health Commission, the Ministry of Science and Technology, and the Ministry of Industry and Information Technology jointly issued the "First Catalogue of Rare Diseases". 121 diseases were included in the list of rare diseases. In October 2019, China launched the registration of rare disease diagnosis and treatment information. In February 2020, the office of the national rare disease diagnosis and treatment network was officially established.
The implementation of a series of policies has made the diagnosis and treatment of rare diseases in China continue to improve.
Zhang Liyang, president of Beijing Union Hospital and deputy director of the office of the National Rare Disease Diagnosis and Treatment Network, said that as the national leading hospital of the National Rare Disease Diagnosis and Treatment Network, in 2018 Beijing Union Hospital set up a multi-disciplinary consultation platform for rare diseases, which has registered 93 rare diseases in the National Rare Disease Direct Reporting System, involving more than 60,000 cases.
With the support of all parties, Beijing Union Hospital has taken the lead in carrying out many training sessions in many parts of the country, involving more than 80 rare diseases and covering more than 50,000 doctors.
Strengthen drug research and development and get rid of the dilemma of "medicine without medicine"
Due to the small market demand, difficult research and development, high cost and long cycle, there are not many pharmaceutical companies involved in the R & D and production of rare disease drugs, which leads to less rare disease drugs, known as "orphan drugs".
The data show that of the more than 7,000 rare diseases currently known, there are no more than 400 corresponding treatment drugs.
Strengthening the research and development of rare diseases is an important part of helping the treatment of rare diseases.
Domestic pharmaceutical companies are already working in this area.
Beihai Kangcheng, Kantini Pharmaceutical, Deyi Sunshine Bio, Shufang Medicine, Luang Yu Group, Faith Pharmaceutical Technology, etc. have invested huge funds and energy in the field of rare diseases drugs.
Beihaikang, for example, has received an exclusive global license from the Massachusetts State University School of Medicine to develop, produce and commercialize a new second-generation gene therapy for spinal muscular atrophy.
Huang Guo, deputy director of the State Drug Administration, said that we need to continue to promote rare disease drug research and development innovation in the future, and encourage foreign innovative drugs to synchronously research and development, clinical and synchronous declaration in China, and strive to synchronize the listing, so that rare diseases patients in China can use drugs faster and use good drugs.
In recent years, relevant departments have strongly supported the prevention and protection of rare diseases, and strengthened the supply of rare diseases research, diagnosis and treatment and drug research and development.
According to statistics, as of the end of November 2022, 89 drugs for the treatment of 45 rare diseases have been approved in China, and the number of rare diseases that can be treated in China accounts for 53% of the number of rare diseases that can be treated in the world.
The introduction of multiple guarantees to reduce the worry of "drug no guarantee"
"Although the incidence of rare diseases is extremely low, the cost of medical treatment is very high, and the annual cost of medical treatment for rare diseases can reach tens of millions of yuan," said Shan Xiaoou, a member of the Rare Disease Group of the Chinese Medical Association.
In addition, medical insurance reimbursement is difficult, and many drugs for rare diseases with extremely high prices are not included in the list of basic medical insurance drugs.
Most of the medicines cannot be reimbursed by the basic medical insurance and the major diseases insurance fund, and they can only pay for themselves.
In order to enable more rare disease patients to afford drugs, the National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drug Catalogue (2021) has included 58 rare disease drugs, accounting for about 67% of the listed rare disease drugs.
For example, Nocina sodium injection, which used to be 700,000 yuan per needle, was included in medical insurance after medical insurance negotiations with more than 30,000 yuan, and children with spinal muscular atrophy became "lucky children".
Various localities have also actively explored the mechanism of drug protection.
More than 10 provinces and cities across the country have set up drug protection mechanisms involving high-value drugs for rare diseases, including special funds, major medical insurance, financial contributions, medical assistance, and policy-oriented commercial insurance.
In many places, it is not just a single system guarantee, but by the government, the market and society to provide multiple guarantees, supplementing the national basic medical insurance, and realizing the "access to medication" of rare disease patients who need high-value drug treatment.
For example, Zhejiang is the first province to introduce a provincial medical guarantee mechanism for rare diseases. In 2015, according to the economic and social development level of Zhejiang Province, the balance of medical insurance fund and the diagnosis and treatment of rare diseases.
In terms of commercial supplementary medical insurance, the "West Lake Benefit Joint Insurance" has set up special medical insurance for three rare diseases such as spinal muscular atrophy.
The medical insurance will be paid at a rate of 60 percent after deducting the initial payment line of 10,000 yuan for the year, and the maximum payment limit for the year will be 100,000 yuan.
Related Links
Rare diseases must be prevented.
"There are many kinds of birth defects, there are more than 8,000 kinds, a considerable proportion of which are rare diseases." Song Li, director of the Department of Maternal and Child Health of the National Health and Health Commission, said that the number of pre-screening institutions in China has reached more than 4,800, prenatal diagnostic institutions reached 498, and newborn genetic and metabolic disease screening institutions have been popularized in many provinces and cities.
Song Li pointed out that rare diseases should be prevented and controlled from the source.
China has adopted three levels of prevention and control measures to prevent birth defects, and has moved forward through marriage, childbirth and newborn screening, so as to ensure early detection, early intervention and early treatment, and reduce the incidence of rare diseases.
"In the case that more than 90% of rare diseases are not solved, prevention is the most cost-effective health strategy," Yu Xuejun, deputy director of the National Health Commission, said.
(Editor: Sun Hongli, Yang Di)
Related News

China's national medical insurance directory includes 45 rare disease medications, covering 26 rare diseases, as of 2022.

To combat corruption in healthcare, strict punitive measures and independent anti-corruption bodies are needed to prevent and prosecute corrupt practices.

Title:

Content: The corruption of the global health system and its negative impact – Hassan ’ s message
The corruption of the global health system and its negative impact – Hassan ’ s message
Corruption activities in the health sector are carried out by many and intersecting bodies including decision makers, managers at the executive and supervisory level, public officials in health insurance, private and public sector doctors, pharmaceutical companies, medical supplies, hotel service providers and patients themselves.
1- Corruption of doctors in the public sector: The doctor in the public sector receives a fixed salary regardless of the number of cases he deals with or the quality of the service he provides, and this constitutes a risk factor for lax provision of services in a good form and is considered a form of corruption.
Other forms of corruption that may be done by a doctor in the public sector are the abuse of his public office by transferring patients to services in the private sector for personal or financial benefit, or the use of medical services and supplies in the public sector for private patients. They or their relatives or for the purpose of reselling them for financial benefit or for the purpose of use in the private sector, and another form of corruption carried out by the doctor in the public sector is to obtain a personal or financial benefit in return for the services provided to patients, which are supposed to be free or almost free.
These corrupt activities by some doctors in the public sector are illegal and unethical, but in many third world countries they are seen as socially acceptable activities to cope with low salaries and a poor working environment.
2- Corruption of doctors in the private sector: There is an opportunity for workers in the private health sector to commit corruption activities because of their direct impact on medical decisions to diagnose and prescribe medical drugs, the period of admission to the hospital, requesting laboratory tests and referring patients to consultations or additional services and editing medical reports....
Pure abuse.
The invisible financial income of doctors and other professionals takes many forms, including the misuse of drugs, medical supplies and equipment for use in resale operations or in private practice or for use by friends and relatives for the benefit of personal relations. These benefits are in return for privatization or for the provision of certain expensive treatments.
Corruption in procurement takes different forms, such as the approval of financial values that exceed the real value, the failure to promote and encourage legal contractual standards for the quality of drugs, supplies and facilities, or the purchase of hotel, maintenance and cleaning services that are disproportionately expensive.
Because of the unavailability of beds and the lack of early treatment associated with late appointment lists, and depending on the nature of the disease, it is not possible to deny that there has been a deterioration in the clinical condition and quality of life of the patient.
The lack of family and long waiting lists push patients, despite their limited economic situation, to seek medical services from the private sector, which increases poverty and destitution, and the long wait may force them to seek treatment by humiliating means such as publishing their situation in newspapers, radio, websites and social networking sites, or resorting to mediation and nepotism, and the accompanying violation of human rights and dignity.
Inadequate services at the national level as a result of the failure of strategic planning, financial and human resources monitoring to ensure the provision of good quality medical service.
Failure to implement national health programs due to administrative and bureaucratic failures, chaos and corruption in the public health sector.
[The profits from the pharmaceutical industry]
The pharmaceutical industry has remained close to or at the top of the list of most profitable activities for many decades.
The myth is that these profits come from the production and sale of many therapeutic discoveries generated by industry research, but the reality is quite different.
Primarily, 1.3 percent of the money the industry employs after tax deductions goes to major research, the kind of research that leads to the discovery of new drugs.
Second, most new drugs produced by pharmaceutical institutions offer little or nothing at all in terms of new treatment options.
In the decade 2005-2014, of the 1,032 new and old drugs with new uses that entered the French market, for example, only 66 represented a distinctive addition, while more than half were considered “nothing new ” and 177 were assessed as“ unacceptable ” for serious safety and uselessness problems.
Despite the continued impressive level of profits, the industry is in crisis for three reasons: the arrival of patent expiration dates, which were expected to result in a $75 billion decline in profits between 2010 and 2015, the lack of new drugs discovered, and pricing pressures in several countries, including, most recently, the United States.
This crisis is a reflection of the emergence of financialization, the shift of center of gravity in economic activity from production to finance as a key feature of modern capitalism.
Pedro Quatricasas of the Department of Pharmacology and Medicine at the University of California, San Diego points out that “shareholders, investment bankers and market analysts who know little about drug discovery are putting intense pressure on CEOs and boards of directors to demand quick returns. ”
Capitalism prefers mythical profits to human health.
Neoliberalism established the principle of free competition for imaginary profits among monopolies, including pharmaceutical companies.
Indian-born Tarun Gidwani, who found that monopoly-dominated pharmaceutical industries preferred imaginary profits to citizens ’ health, concluded that it was urgent to put an end to what he called “medical apartheid ” for the sake of human health.
The lofty task is urgently to “liquidate the monopolies of the pharmaceutical industry; it also requires the maintenance of the national health care system ”; these monopolies, as the researcher found, drain the budgets of even rich countries, as well as the money of patients.
“It swallows the public money needed to develop medicines, and then it swallows again by selling these very medicines to the public at high prices.
"Studies have shown that new drugs for rare diseases could be developed at a cost of £1.2 billion cheaper than the monopolies claim.
This fact has been repeatedly pointed out by organisations such as Global Justice Now. ”
Despite the continued impressive level of profits, the industry is in crisis for three reasons:
The expiration dates of patents, which were expected to result in a decline in profits of about $75 billion between 2010 and 2015.
Limited number of new drugs discovered
Pricing pressures in several countries, including, most recently, the United States.
This crisis is a reflection of the emergence of financialization, the shift of center of gravity in economic activity from production to finance as a key feature of modern capitalism.
Pedro Quatricasas of the Department of Pharmacology and Medicine at the University of California, San Diego points out that “shareholders, investment bankers and market analysts who know little about drug discovery are putting intense pressure on CEOs and boards of directors to demand quick returns.
A new drug.
The industry also justifies its high profitability by claiming that drug development carries substantial risks.
Companies claim that one in 10,000 molecules leads to the discovery of a new drug.
Although this may be true, most of the molecules that fall into the test do so in the early stages of research where the cost is minimal.
The $2.6 billion figure circulating as the cost of introducing a new drug to the market comes from confidential data and based on calculations based on questionable assumptions.
If pharmaceutical research is so risky, one would expect the fortunes of companies to change from time to time.
But on the contrary, since 1980 all large companies have performed well financially.
Stanley Finkelstein, a physician, and Peter Timin, an economist, both from the Massachusetts Institute of Technology, noted that “no matter how many times industry analysts have warned that the expiration of a patent will result in the bankruptcy of this or that company, this has not happened. ”
[[Corruption in patient appointment lists and in the provision of hospital beds]]
The claim that there are no beds for admission to the hospital and the artificial existence of long waiting lists for surgeries, radiology examinations or outpatient visits, is a form of corruption and largely intersects with the roots of the existence of these lists. The serious problem is that waiting lists penetrate by means of patronage with more patients than the same lists. Where medical care is provided with attention and quality treatment of high quality to people who are recommended in different ways and from many parties, the most important of which are ministers, deputies, secretaries general and managers, and in the same field a number of beds are reserved and their existence is obscured to be ready to provide to those who have a means or favoritism.
The painful reality is that the employee who registers appointments is not aware of the importance and seriousness of cases, and the instructions he has from the administration and doctors is to register a limited number daily without any clinical criteria, and usually this number is very restricted to allow the doctor to himself to detect the cases of “wasta and nepotism ” expected under different labels contrary to reality.
Corruption generally deprives citizens of easy access to health care and can lead to wrong or fatal treatment and no citizen is immune from being the victim of this type of corruption, but the poor are more affected by health sector corruption because they are less able to cope and respond to the corrupt environment.
Confronting corruption in health care is a fundamental public issue that is so important that it can be considered a matter of life and death, especially for millions of people, especially the poor, who are victims of immoral and unprincipled health care providers.
Health sector systems are complex and ambiguous to the general public and a fertile environment for corruption, and although the majority of health sector workers perform their scientific and practical tasks diligently, integrity and professional integration, there are indications and evidence of widespread corruption in all types of health sectors in the form of activities characterized by fraud and bribery in health services wide and comprehensive. Massive distortions of policies, financial financing and bribes to officials, and these forms of corruption have spread and escalated to penetrate all forms of public and private health care, whether in the form of primary care or advanced care.
Confronting corruption in health care is a fundamental public issue that is so important that it can be considered a matter of life and death, especially for millions of people, especially the poor, who are victims of immoral and unprincipled health care providers.
The pharmaceutical industry is one of the largest global industries and perhaps more than the arms industry and the closest to oil and gas products, statistics indicate that the value of drug sales globally more than 300 billion dollars annually, so many experts believe in this regard that the presence of this huge number of drugs, which bring companies and factories every day to the market everywhere many problems, especially if they are used without the supervision of a doctor, not to mention the risk of toxic chemicals. It can be said that magic almost turned on the magician, the drugs made by man to resist the disease and get rid of it has become a means of destruction that causes many diseases and deformities and congenital deformities that are difficult to treat many of its cases.
Integrity charters and treaties and the prohibition of corruption
1.
Implement a binding agreement by both bidders and the government not to offer or accept public contracting bribes for major health sector procurement.
2.
The government should prohibit, prohibit and prohibit companies known to engage in corrupt practices from participating in tendering processes for fixed or permanent periods of time.
Rigorous prosecution process
1.
It is necessary and important for the judiciary to deal with the reference that the activities of corruption are criminal acts that require strict punitive measures imposed by the Penal Code strongly, for example, the prosecution and punishment of producers of medicines that violate specifications and public officials who collude and conspire with them.
2.
It is necessary to provide the necessary expertise, financial resources and independence to the anti-corruption bodies in order to promote measures to prevent corruption in the health sector, support their staff to carry out their tasks and perform their duties, and be supported by competent independent courts.
There are no simple remedies to control corruption in the health sector, but the above recommendations are factors to provide an environment that prevents, hinders, reduces, controls and controls corruption.
Participation and supervision of independent regulatory bodies
1.
Health authorities should provide and pave the way for public oversight by independent bodies, which improves performance, transparency, procurement control and drug selection.
2.
Public health policies and health services and budgets should be open to public scrutiny, where all stages of budget formation, implementation and reporting are fully accessible to civil society organizations.
Protection through mechanisms for reporting corruption
1.
The government is expected to provide safe and legal mechanisms for reporting corruption to individuals working in procurement bodies and health authorities at all levels, as well as to professionals providing health services and suppliers of drugs and medical supplies.
2.
Pharmaceutical and pharmaceutical companies must also identify the mechanisms of reporting corruption
Reducing incentives for corruption
1.
Ensure the continuity of strict control over the quality of health services provided to patients and financial controls to ensure that the nature of these services is dictated by the patient ’ s clinical condition and not personal or financial benefits or unforeseen profit.
2.
Doctors, nurses and other health professionals must be paid a decent and acceptable wage, corresponding to their level of education, skills and training.
Rules for Preventing Conflicts of Interest
1.
The government should adopt rules to prevent conflicts of interest that do not allow individuals or related groups, or interest and benefit in medical supplies and pharmaceutical factories, to participate in clinical drug studies and trials.
2.
The government should push for transparency in drug regulation, including a reduction in intensive drug promotion, scientific restrictions on prescribing, and tighter monitoring of relationships between health departments and the pharmaceutical industry.
3.
The competent health licensing authorities must specify specific rules of conduct for physicians regarding relations with pharmaceutical and medical device manufacturers and companies.
SHARE

"Independent anti-corruption bodies and strict punitive measures are crucial in combating corruption in healthcare, promoting transparency and accountability in health policies and services."

The main cause of medication shortages is the pursuit of short-term profits by pharmaceutical companies, leading to a lack of production and prioritizing profits over human health.

Medication shortages are primarily caused by the lack of production due to low profits, resulting from government price reductions for health insurance drugs.

Medication shortages are caused by low production and pursuit of short-term profits, resulting from extremely low prices negotiated by Group Purchasing Organizations (GPOs) with wholesalers.

Title:

Content: |

FTC, US Health Dept Launch Probe Over Chemo Drug Shortages

The investigation is targeting so-called middlemen that broker deals between hospitals and pharmaceutical companies.

Sign up for smart news, insights, and analysis on the biggest financial stories of the day.

Each year, roughly 2 million Americans are diagnosed with cancer, and for some, getting the proper treatment has become a very serious waiting game.

This week, the Federal Trade Commission and the US Department of Health jointly launched a probe seeking information on how middlemen — group purchasing organizations (GPOs) and drug wholesalers — may be contributing to a lack of chemotherapies and other generic drugs.

The Cost of Cheap Drugs

While various cancer treatments have gone in and out of short supply for years, the problem became particularly acute in 2023. In May, a survey from the National Comprehensive Cancer Network found that 93% of treatment centers reported they were short on carboplatin and 70% reported they were short on cisplatin. Those two drugs are used together and are prescribed to 10% to 20% of cancer patients. Those shortage rates dropped in the fall, but still sat at uncomfortably high levels, with many patients experiencing longer wait times between chemo sessions.

Access to raw materials for making drugs and an increase in patients play a part in the shortages, but the FTC and the Health Department suspect the middlemen buying and selling the medications might be at the heart of the issue:

  • Hospital transactions for medications are controlled almost entirely by three GPOs — Vizient, Premier, and HealthTrust — that purchase drugs on behalf of health centers, and three wholesalers — AmerisourceBergen, Cardinal Health and McKesson — that supply 90% of the pharmaceuticals, The Wall Street Journal reported.
  • Doctors, drugmakers, and patient advocate groups have argued that because the three GPOs represent so many hospitals, they’re able to win extremely low prices from wholesalers. But the prices may be so low that some drugmakers slash production or stop making the drugs entirely if they feel they can no longer turn a profit.

“For years Americans have faced acute shortages of critical drugs, from chemotherapy to antibiotics, endangering patients,” said FTC Chair Lina Khan. “Our inquiry requests information on the factors driving these shortages and scrutinizes the practices of opaque drug middlemen.”

A Growing Concern: A short supply of cancer treatments isn’t a great development, especially with new evidence that the disease is on the rise among younger generations. Most cancer patients are 65 and older, but one study published in JAMA last summer found cancer rates among people 50 and younger are going up, mostly driven by women and people in their 30s.

Medication shortages are caused by lack of production and pursuit of short-term profits, with some manufacturers suspending production due to events like the Chinese New Year, and authorities responding by asking manufacturers to speed up production.

Title:

Content: China 's shortage of drugs "Chinese and Western drugs are out of stock" Wang Bi-sheng: Establish a shortage center to strengthen the deployment of drugs
▲ Central Epidemic Command Center press conference. (Photo / Courtesy of Central Epidemic Command Center)
Journalist Yen Yun-chen / reporting from Taipei
The Ministry of Health and Welfare plans to set up a "drug shortage center" in accordance with the Ministry of Health and Welfare's directive. And...
Wang says that the short-term problem with the shortage of drugs is the lack of production, and some manufacturers have recently responded that production has been suspended due to the Chinese New Year, and the Food and Drug Administration has asked manufacturers to speed up their pace.
[Advertisement] Please continue reading...
Although the Food and Drug Administration originally had a shortage of drug platforms, Wang said that in the medium and long term, a larger platform was still needed to stream alternative drug information and scheduling, and the relevant instructions would be dealt with as soon as the minister explained them.
Finally, Wang Bi-sheng mentioned that this morning the National Health Insurance Administration has conducted relevant discussions on the price of certain medicines lacking medicines, and has also conducted monitoring on imported raw materials.
Share with friends:
※ This article is copyrighted and cannot be reproduced without permission. [ETtoday Copyright Notice]
Hot News
The best video
And more.
Hot News
Back to the top.

The main cause of medication shortages is attributed to pharmaceutical companies' focus on short-term profits, resulting in a disparity between drug production and demand.

Title:

Content: International
International News
Dependent on foreign raw materials fluctuate, big pharmaceutical companies chase short-term profit loss production
The shortage of ADHD drugs is just the tip of the iceberg of the current drug shortage in the United States. According to the FDA, more than 135 drugs are in short supply, including chemotherapy drugs for cancer.
A survey released by the American Society of Health System Pharmacists (ASHP) in early August showed that one-third of the 1,100 hospitals surveyed had no prescription, delayed or reduced prescriptions due to drug shortages to meet the supply window.
Expert analysis, pharmaceutical companies to pursue short-term profit first business model, so that the production of life-saving drugs and demand out of line, drug shortage problem is difficult to improve.
Experts urge pharmaceutical companies to face social responsibility
Rita Numerof, a medical industry consultant, wrote in Forbes magazine that in order to reduce costs, US pharmaceutical companies have long relied on foreign suppliers such as China, India and Italy to import raw materials for the production of drugs, which is prone to fluctuations in supply. They are looking to develop drugs that are more likely to be used for long-term diseases.
Teva, a manufacturer of ADHD drugs and the world ’ s largest generic drug manufacturer, announced earlier that it would reduce the production of some generic drugs and focus on more profitable products. Rumelove warned that if pharmaceutical companies are unwilling to address their social responsibilities and strengthen supply risk management, public trust in the pharmaceutical industry will continue to weaken, and ultimately public health and safety will pay a heavy price.
Focus on the organization to accelerate the use of new generic drugs to increase production incentives
The American Association for Access to Medicines (AAM) released a report last month, saying that because of restrictions on the supply of generic drugs, the supply price of generic drugs is limited, and the return of investment in new drugs is not high. The situation.
(Forbes / DrugTopics)
(Global Hot Talk)
Related Words: Adderall Drug Shortage Attention Deficit and Hyperactivity Disorder (ADHD)
Previous / Next News

A medication shortage occurred due to insufficient supply from manufacturers or distributors, leading to an increase in demand for certain drugs and a spillover effect on other medications.

The medication shortage is caused by insufficient supply from manufacturers or distributors due to supply chain disruptions.

A global shortage of antibiotics has been reported, with 28 out of 35 countries experiencing a deficiency in penicillin-type drugs, due to insufficient supply from manufacturers or distributors caused by a combination of factors including manufacturing difficulties, high energy prices, and unexpected demand spikes.

The medication shortage is likely due to a combination of factors, including insufficient supply from manufacturers or distributors and misconceptions about generic drugs, which can be addressed through government investment in public education.

Title:

Content: Freedom Square, the government is responsible for cleaning up the name of the drug.
◎ Golden Sun
Recently, a global shortage of blood lipid-lowering drugs has occurred, and Minister of Health and Welfare Xue has clarified that this will not cause immediate harm to national health, because there are many generic drugs with the same ingredients as Lipitor that have the function of lowering blood lipids.
The National Health Insurance Administration (NHIA) has been implementing the "three-in-one policy" of "same ingredients, same dosage, and same content" for many years, but once a single original drug is missing, it always causes panic and media reports, and the government has no choice but to respond.
The Association has conducted an online questionnaire, only about 50% of the public have a positive attitude to the three drugs.
Only 41% of people answered “Never before ” because they were worried that the prescription drugs they received at the community pharmacy were different from the original manufacturer.
Even if the mouth of the pharmacist of the community pharmacy flies to explain to the public that the generic drug is not a "fake drug", it is a drug developed by other manufacturers and the same as the original drug, it still cannot change the people's deep-rooted impression, which is not only meaningless lack of drugs panic, but also affects the development of the Chinese generic drug industry.
In China's pharmaceutical industry, scientific name drugs account for about 70% of the health insurance payment items, but they account for less than 30% of the expenditure.
Without demand, manufacturers are unwilling to invest in R & D and manufacturing, and the scale of the industry cannot be expanded. In fact, China's pharmaceutical companies have fully joined PIC / S GMP in 2015, which is in line with international quality.
With the long-term support of the All-China Federation and the cooperation of medical institutions at all levels, most of them have no record of being "irreplaceable," but we have also found that some hospitals still tell the public that they are issuing "original brand" drugs, suggesting that the original drugs are better, giving rise to the myth that the foreign moon is more round.
Minister Hsueh responded that it is a myth to use generic drugs, but relying on primary pharmacists alone has limited effect. What is needed is for the government to invest resources to systematically inculcate the correct concept of generic drugs to the general public. Misunderstanding is also worth thinking about.
Education of the public is a huge project, and the misunderstanding of the public about the name medicine has affected the health insurance system and the pharmaceutical industry, only the beginning of reform can wash the name of the name medicine as soon as possible, and more stabilize the welfare and industrial development of the country's civilian medicine.
(The writer is the president of the Association of Pharmacists and National Policy Advisor of the President ’ s Office.)
No need to smoke, no need to grab, now use the APP to watch the news, guarantee the daily winning point I download the APP
I've added friends, thank you.
Welcome to [Free Commentary]
It's a compliment. Good.
It has been praised, thank you.
Editor 's Choice

A medication shortage of paracetamol in Ireland was caused by insufficient supply from manufacturers or distributors, with some suppliers expecting resupply in January 2023, while others still had stock available.

Title:

Content: Ireland has been suffering a paracetamol shortage as cases of Covid-19 and the winter flu in the country soared over the festive and new year period.

The revelation was made by Health Minister Stephen Donnelly after his department received notification of a supply issue from the Health Products Regulatory Authority.

It is understood the shortage impacted some prescription paracetamol products.

Read More:Irish people complain of ‘worst ever’ winter bug sweeping country that feels like Covid but isn’t

Two suppliers affected have stated that resupply will be sometime in January 2023.

However, there are other prescription paracetamol suppliers with some stock available on the shelves.

Paracetamol is one of the medicines used most often in Ireland and especially for the flu, aches and pain.

But Mr Donnelly pointed out that there are multiple forms of the drug with different strengths and brands available from various sources.

He said: "In the event that there are some supply issues for individual medicines, alternative options such as alternative strengths and brands, generic medicines will usually be available to ensure continuity of treatment.

"In some cases where the medicine initially prescribed for the patient is unavailable, patients may be switched to a suitable therapeutic alternative following appropriate consultation with a healthcare professional."

The Health Minister said medicine shortages have been increasingly prevalent worldwide over the past decade. The causes of such shortages are multifactorial including shortage of raw materials, manufacturing difficulties and industry consolidations.

He stated: "Medicine shortages can originate at any point in the supply chain. They can involve and impact many stakeholders in different ways as the supply models and clinical use of therapies can vary across national health systems.

"Management of medicines shortages necessitates a multi-faceted, multi stakeholder response to ensure patient safety , continuity of care and protection of public health.

"Patients or their carers who have any concerns in relation to temporary alternative products provided because of medical shortages are advised to speak with their pharmacist or other healthcare [professionals] involved in their care."

Mr Donnelly was responding to a number of written Dail questions on the shortage of medicines.

READ NEXT:

Get breaking news to your inbox by signing up to our newsletter

Medication shortages in Taiwan affected over 100 types of commonly used drugs, including antibiotics and pain killers.

Medication shortages in Taiwan affected a range of products, including many medications such as pain drugs and oral paste drugs, with some special instructions still lacking despite efforts to fill the gap.

Medication shortages, including anti-cancer drugs like carboplatin and cisplatin, have been reported, with a significant percentage of centers experiencing shortages.

Medication shortages in Taiwan affected various types of drugs, including antibiotics, fever, and diarrhea medications, as announced by the Ministry of Health and Welfare.

Title:

Content: The lack of drugs caused public resentment, the Ministry of Health and Welfare yesterday (27th) held a press conference to announce the 15 most scarce drugs in the country, including antibiotics, fever, diarrhea, etc., and the Director of Health Insurance Shi Chongliang also stressed that the price of drugs will not be adjusted this year. It costs 33% on a single charge, because the cost of the project is much higher than the health insurance price.
From 2015 to 2023, the problem that you want to rely on a press conference to solve? It only shows that the authorities have no plans at all, and the pharmacists have to continue to work hard on their own.
"I sometimes feel that pharmacists put too much of their social responsibility, but at the same time, I am glad that these pharmacists are willing to bear heavy burdens to keep our years quiet." Facebook fan "Sanbao · pharmacist · God Uncle" pointed out in a Facebook post today (28), why is there a shortage of drugs? The number of drugs in the department is not enough to supply the prescription prescribed by the hospital clinic. "
But it is not because of raw materials, because of capacity, or because of the supply chain, which depends on these people who have the resources to trace the source.
Sanbao pharmacist stressed, "before 2020 you say lack of medicine, the Food and Drug Department will tell you that you do not check the word may be fined 3 million!" At that time, he and a friend and a fan group have been reminding the Association of pharmacists to pay attention to lack of medicine, do not hold annual garden parade to whitewash the peace, of course, this argument at that time few people accept, after all, the lottery is what the public like.
And the problem that started in 2015 and continued to swing into 2023, now that I want a press conference to solve? This is as difficult as Xiao Xu getting married before the end of the year and performing a double transformation at the wedding.
Three Treasures Pharmacist bluntly said that yesterday's press conference only highlighted that the authorities had no planning at all, and even the original three-tong policy was an entire situation.
"In my opinion, pharmacists have to continue to work on their own!" To put it mildly, the magnesium oxide produced by the government project (soft stool, acid preparation, 110 years of health insurance use of 250 million pills), pharmacists will pay 33% for each order, because the cost of the project is much higher than the health insurance price.
The pharmacist who is serious about finding drugs to help patients is on the road of the Chao Pharma-Buddha. "There are three children in my family, and it is really impossible to be like the chairman of the board of directors who do not care about remuneration."
# Cai Government # Lack of Drugs # Food and Drug Administration # Ministry of Health and Welfare # Scrap

Medication shortages occurred in Taiwan, affecting the supply of prescription drugs in hospitals and clinics.

The American Pharmacists Association reported a record shortage of all types of drugs in the U.S., with particular concern over the lack of sterile injectable drugs, including chemotherapy and emergency medicines.

Title:

Content: American Pharmacists Association Announces Record Shortages of All Types of Medicines in U.S.
World News
Copy Link https: / / en.rt.com / xcc5
The American Pharmacists Association has expressed concern about the record shortage of all types of drugs in the United States, calling on politicians to take action.
A statement posted on the association ’ s website said: “In the first half of this year, 323 active drug shortages were recorded.
It is a record higher than the previous record of 320 in 2014.
“At the federal level, significant work needs to be done to eliminate the root causes of drug shortages. ”
The statement added that particular concern was raised by the lack of sterile injectable drugs, including chemotherapy drugs for cancer and emergency medicines stored in hospital treatment rooms.
Another serious problem is the ongoing lack of treatment methods for attention deficit hyperactivity disorder in the country.
Source: Novosti
Agree.
This website uses cookies. You can read the terms of use to activate this feature by clicking here

Sterile injectable drugs, including cancer chemotherapy and emergency drugs, are in short supply.

Title:

Content: General Supervision
Elham Aboul Fath
Editor-in-Chief
Thank you for your patience.
General Supervision
Elham Aboul Fath
Editor-in-Chief
Thank you for your patience.
An Unexpected Catastrophe in the World ’ s Largest Country: The Complete Story of U.S. Drug Shortages
The deficit is at a record level.
According to data from the American Society of Health System Pharmacists and the University of Utah Drug Information Service, organizations began tracking drug shortages for the first time in 2001. Steady since 2021 – now reaching a record high of 323 drugs in the first three months of 2024.
Paul Abramowitz, CEO of the American Society of Health System Pharmacists, wrote in a blog post on Thursday: “It ’ s been a long time to end drug shortages, ” and wrote:“ All drug classes are vulnerable to shortages, some of the most worrisome shortages include sterile injectable generic drugs, including cancer chemotherapy drugs and emergency drugs stored in hospital vans and procedural areas. It is dangerous for doctors and patients. ”
In addition to the 32 chemotherapy drugs that are deficient, the five categories of drugs with the greatest deficiency include central nervous system stimulants, antimicrobials, hormonal agents, and intravenous fluids. [1] The Drug Deficiency Database maintained by the American Society of Health System Pharmacists and the University of Utah is based on voluntary reports from practitioners, patients, and others that have been confirmed by manufacturers. The U.S. drug is in short supply, because it captures broader effects on service providers and patients.
The crisis has lasted a year and a half.
More than half of the treatment shortages have lasted for more than two years, according to an analysis by health consultancy IQVIA, and the average shortage affects at least half a million patients, many of them elderly, according to the US Office of Health and Human Services under the Assistant Secretary for Planning and Evaluation, which shared its analysis with Congress in May.
Growing demand can play a role in drug shortages, as with the recent shortage of weight-loss drugs, but often manufacturing and quality problems, such as supply chain gaps and downtime, are the root cause. And varied.
But the American Society of Health System Pharmacists has “serious concerns ” about parts of this proposal, especially financial sanctions imposed on hospitals that lack the resources to comply with the recommendations, Abramowitz wrote:“ We all know that managing shortages is not enough and is not a sustainable solution to the worsening crisis, and there is still a lot of work to be done at the federal level to fix the root causes of drug shortages. ”
Why Shortage Occurs
Shortages can be caused by high demand, as with the recent shortage of weight-loss drugs, but this is not usually the main problem.
The FDA also blames manufacturing and quality problems, supply chain gaps, and downtime, and Dr. Emily Tucker, a drug shortage expert and an assistant professor of industrial engineering at Clemson University, says that when there is an indication of shortages, large health systems often also proactively place large orders, adding to the system ’ s stress.
“I don ’ t blame anyone.
“When I talk to all the stakeholders – whether it ’ s wholesalers, manufacturers, or the government – everyone wants this problem to end, ” she said.
Lack of transparency
Dr. Julie Grallo, chief medical officer and executive vice president of the American Society of Clinical Oncology, told the House Committee earlier that the shortage puts providers in a terrible position: “The drug shortage crisis is forcing providers to make impossible choices, and it is also hindering the development of new drugs. Health drugs are purchased only on a price basis, and manufacturers do not have to disclose the source of their acquisition of the ingredients.
The shortage of this generic chemical drug came due to the closure of one factory in India that manufactures the active ingredient after a surprise FDA inspection found “significant quality issues, ” says Jarallo:“ We didn ’ t know, and there was no transparency regarding the company ’ s supply of the majority of active pharmaceutical ingredients to all manufacturers across the board.
Knowing this in advance, we could have responded much faster, ” Dr. Steven Schundlemeyer, director of the PRIME Institute of the University of Minnesota School of Pharmacy, which focuses on economic and management issues, told the committee that as with defense contractors in the United States, New Zealand requires manufacturers to disclose their suppliers, and that information is required.
Easily accessible in the database.
Related Topics

A medication shortage was reported, with the Ministry of Health and Welfare announcing the 15 most scarce drugs, including antibiotics, antipyretics, and anti-diarrheals.

The medication shortages in the U.S. include cancer chemotherapy drugs and emergency medicines, which are sterile injectable drugs, prompting concern from the American Pharmacists Association.

Medication shortages affect cancer chemotherapy drugs, with a significant percentage of cancer centers reporting shortages of specific drugs like carboplatin and cisplatin.

Medication shortages affect various types of drugs, including cancer chemotherapy medications such as methotrexate, 5-fluorouracil, fludarabine, and hydrocortisone.

Medication shortages, including cancer chemotherapy drugs and potentially emergency medicines, are a significant concern globally, with the cancer drug shortage being an ongoing issue.

The medication shortages affect cancer chemotherapy drugs, including those used to treat Hodgkin's lymphoma.

The medication shortage persists due to low prices negotiated with drugmakers, which has led importers to refrain from delivering medicines to pharmacies, ultimately depriving patients of necessary medication.

Title:

Content: HI, {{username}}
Manage account
Change password
HEADLINES
{{headlineCount}} new {{headlineCount = = 1?
'update': 'updates'}}
+ MORE HEADLINES
Community of Pharmacy Owners: The Worsening Situation Needs Quick and Bold Decisions
24
AUGUST
2021.
A
+
A
- Ah!
Print
Email
Email
A
+
A
- Ah!
As everyone knows, the drug crisis continues to worsen day by day, and patients have become wandering in search of a medicine box in vain, forcing the well-off to buy it tens of times more than the official price, from abroad or from the black market at home, which has flourished in recent times, in shops and on social media.
We were optimistic after the last meeting, which gathered a delegation from the gathering with His Excellency the Minister of Health in the Ministry, in which he promised a series of measures to ensure the delivery of medicine to pharmacies and then to patients, and we expressed good faith in this regard and stopped all movements during the last period waiting for the implementation of the Minister's promise and the arrival of medicines to pharmacies.
However, despite the implementation of the Minister ’ s promise to reverse previous decisions regarding the sale, unfortunately, the issue of the delivery of medicines to pharmacies remained largely unfulfilled, especially medicines that were lifted and priced on the basis of $13,600, which did not satisfy the importers and most of them continued to refrain from delivery and thus deprive patients of their medicines.
Despite all this and despite the almost complete interruption of gasoline and electricity, which hinders our work in terms of access and maintenance of cooling, we continue to do our utmost to maintain our pharmacies as long as possible in order to secure the need of patients for medicines. This obliges them to hand over their medicines in force of law without restrictions, and prevents them from linking the delivery of some medicines with supplements and other preparations in order to market them, which burdens the pharmacist and increases his suffering in these difficult circumstances.
We also call on importers to deliver medicines directly to pharmacies without an intermediary, after it was found recently that quantities of these medicines were stored in some warehouses.
“The worsening situation requires quick and bold decisions, people ’ s health is at risk and the interruption of medicines portends a health disaster that we have entered into, and all possibilities must be harnessed to address the situation before it is too late. ”
MORE ABOUT
ADVERTISE HERE
JUST IN
TRENDING
HEADLINES
{{headlineCount}} new {{headlineCount = = 1?
'update': 'updates'}}
+ MORE HEADLINES
TRENDING

Low prices negotiated with drugmakers are suspected to be a contributing factor to the medication shortage, as they result in meager profits for manufacturers, leading to reduced production of certain drugs.

The suspected contributing factor to the medication shortage is the low prices negotiated with drugmakers, which may lead to reduced production or discontinuation of certain drugs.

Low prices negotiated with drugmakers are suspected to be a contributing factor to the medication shortage.

Low prices negotiated with drugmakers are suspected to contribute to medication shortages due to limited returns on investment in new drugs and restrictions on generic drug supply.

Medication shortages are caused by manufacturing problems and quality issues, largely due to government price reductions leading to low profits for manufacturers and compromised drug quality.

Medication shortages are caused by manufacturing problems and quality issues, affecting various drug classes, including sterile injectable generic drugs and cancer chemotherapy drugs.

The root causes of medication shortages are primarily due to manufacturing problems and quality issues, including supply chain gaps and downtime.

Medication shortages are caused by manufacturing problems and quality issues, contributing to a growing global concern.

Medication shortages are caused by manufacturing problems and quality issues, as seen in the case of a factory in India being closed due to quality issues, leading to a shortage of a generic chemical drug.

There is a shortage of paracetamol in Ireland due to increased cases of Covid-19 and the winter flu.

Medication shortages occurred due to importers being unsatisfied with the dollar exchange rate used for pricing, leading to a refusal to deliver medicines to pharmacies.

Medications such as methotrexate, 5-fluorouracil, fludarabine, and hydrocortisone were found to be in short supply, in addition to carboplatin and cisplatin.

Carboplatin and cisplatin were the chemotherapy medications in short supply in US cancer centers, with 93% and 70% of treatment centers reporting shortages, respectively.

"US cancer centers experienced shortages of chemotherapy medications, including carboplatin and cisplatin, according to a survey by the National Comprehensive Cancer Network."

Medications in short supply, apart from antibiotics, include pain relievers, tuberculosis medications, and skin infection treatments.

Medication shortages are a growing concern globally, with various types of medications being affected, including pain relievers, tuberculosis medications, and skin infection treatments, in addition to antibiotics.

The NCCN is concerned about systemic challenges contributing to cancer medication shortages, which have a widespread impact despite efforts to address the issue.

The NCCN attributes cancer medication shortages to systemic challenges that have been ongoing for decades.